vs
Enact Holdings, Inc.（ACT）与Organogenesis Holdings Inc.（ORGO）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Organogenesis Holdings Inc.的8.4倍（$312.1M vs $37.2M），Enact Holdings, Inc.同比增速更快（1.7% vs -57.1%），过去两年Enact Holdings, Inc.的营收复合增速更高（2.2% vs -46.5%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Organogenesis Holdings Inc.是一家领先的再生医学企业，专注于开发、生产用于伤口护理、外科修复、运动医学和皮肤病领域的先进治疗产品，主要服务美国及部分国际市场的医疗机构与患者，提供经临床验证的医疗解决方案。
ACT vs ORGO — 直观对比
营收规模更大
ACT
是对方的8.4倍
$37.2M
营收增速更快
ACT
高出58.8%
-57.1%
两年增速更快
ACT
近两年复合增速
-46.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $312.1M | $37.2M |
| 净利润 | $168.0M | — |
| 毛利率 | — | 30.8% |
| 营业利润率 | — | -185.1% |
| 净利率 | 53.8% | — |
| 营收同比 | 1.7% | -57.1% |
| 净利润同比 | 1.2% | — |
| 每股收益（稀释后） | $1.18 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTORGO
| Q1 26 | $312.1M | $37.2M | ||
| Q4 25 | $312.7M | $225.6M | ||
| Q3 25 | $311.5M | $150.9M | ||
| Q2 25 | $304.9M | $101.0M | ||
| Q1 25 | $306.8M | $86.7M | ||
| Q4 24 | $301.8M | $126.7M | ||
| Q3 24 | $309.6M | $115.2M | ||
| Q2 24 | $298.8M | $130.2M |
净利润ACTORGO
| Q1 26 | $168.0M | — | ||
| Q4 25 | — | $43.7M | ||
| Q3 25 | — | $21.6M | ||
| Q2 25 | — | $-9.4M | ||
| Q1 25 | — | $-18.8M | ||
| Q4 24 | — | $7.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | — | $-17.0M |
毛利率ACTORGO
| Q1 26 | — | 30.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 72.6% | ||
| Q4 24 | — | 75.5% | ||
| Q3 24 | — | 76.7% | ||
| Q2 24 | — | 77.6% |
营业利润率ACTORGO
| Q1 26 | — | -185.1% | ||
| Q4 25 | 71.3% | 28.1% | ||
| Q3 25 | 67.4% | 13.7% | ||
| Q2 25 | 70.4% | -12.5% | ||
| Q1 25 | 68.9% | -30.9% | ||
| Q4 24 | 68.9% | 8.1% | ||
| Q3 24 | 74.1% | 5.4% | ||
| Q2 24 | 78.6% | -10.7% |
净利率ACTORGO
| Q1 26 | 53.8% | — | ||
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | -9.3% | ||
| Q1 25 | — | -21.7% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 10.7% | ||
| Q2 24 | — | -13.1% |
每股收益（稀释后）ACTORGO
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.23 | $0.31 | ||
| Q3 25 | $1.10 | $0.11 | ||
| Q2 25 | $1.11 | $-0.10 | ||
| Q1 25 | $1.08 | $-0.17 | ||
| Q4 24 | $1.05 | $0.05 | ||
| Q3 24 | $1.15 | $0.09 | ||
| Q2 24 | $1.16 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $549.0M | $91.4M |
| 总债务越低越好 | $744.9M | — |
| 股东权益账面价值 | $5.3B | — |
| 总资产 | $7.0B | $520.0M |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTORGO
| Q1 26 | $549.0M | $91.4M | ||
| Q4 25 | $582.5M | $93.7M | ||
| Q3 25 | $545.6M | $63.7M | ||
| Q2 25 | $616.0M | $73.1M | ||
| Q1 25 | $639.0M | $110.0M | ||
| Q4 24 | $602.8M | $135.6M | ||
| Q3 24 | $674.9M | $94.3M | ||
| Q2 24 | $711.3M | $89.9M |
总债务ACTORGO
| Q1 26 | $744.9M | — | ||
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | $62.3M | ||
| Q2 24 | $742.4M | $63.8M |
股东权益ACTORGO
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.4B | $300.1M | ||
| Q3 25 | $5.3B | $255.1M | ||
| Q2 25 | $5.2B | $233.2M | ||
| Q1 25 | $5.1B | $242.9M | ||
| Q4 24 | $5.0B | $262.9M | ||
| Q3 24 | $5.0B | $278.5M | ||
| Q2 24 | $4.8B | $263.5M |
总资产ACTORGO
| Q1 26 | $7.0B | $520.0M | ||
| Q4 25 | $6.9B | $598.7M | ||
| Q3 25 | $6.9B | $509.8M | ||
| Q2 25 | $6.8B | $461.1M | ||
| Q1 25 | $6.7B | $467.4M | ||
| Q4 24 | $6.5B | $497.9M | ||
| Q3 24 | $6.6B | $446.3M | ||
| Q2 24 | $6.3B | $443.2M |
负债/权益比ACTORGO
| Q1 26 | 0.14× | — | ||
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | 0.22× | ||
| Q2 24 | 0.15× | 0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
| Premiums | $242.8M | 78% |
| Other | $69.2M | 22% |
ORGO
暂无分部数据
